Yes Flyer, this is a very different company due entirely to savvy management.
l forgot to say in my summary that low strength Bijuva has already been launched and that management see significant organic growth as its primary focus but looking for opportunities in the Women's Health space.
During question time there was a small discussion around an US IPO but this was batted away stating that getting this company into profitability is the main focus.
Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference, page-8
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.40 |
Change
0.140(3.29%) |
Mkt cap ! $374.3M | |||
| Open | High | Low | Value | Volume |
| $4.25 | $4.43 | $4.25 | $618.9K | 141.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2957 | $4.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 968 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |